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UVB Immunosuppression: Vitamin D
or Not Vitamin D? That Is the Question
Hui Xu1 and Craig A. Elmets1
UVB radiation stimulates the production of vitamin D and also has immunosup-
pressive effects. Vitamin D is also known to alter immunological function. Thus, a
relevant question is whether vitamin D is a mediator of the immunological effects
of UVB. In this issue, Schwarz et al. have addressed this issue and have concluded
that although vitamin D has similar effects to UVB on the immune system,
UVB-induced immunosuppression can be achieved without the requirement
for vitamin D action.
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Vitamin D, a molecule formed in the
skin following UVB radiation exposure,
is a major regulator of calcium home-
ostasis and an essential nutrient for bone
health. Children whose diet lacks vita-
min D or who have an inborn error in
vitamin D metabolism develop rickets,
and adults deficient in vitamin D can
develop osteomalacia and osteoporosis.
There is unequivocal evidence that
vitamin D is necessary for bone health;
but, in recent years, there has been great
interest in vitamin D’s extraskeletal
effects. These include protective effects
in colon and breast cancer, preven-
tion of cardiovascular disease, diabetes,
and pre-eclampsia, and modulation
of immunological function. However,
it is important to note that the Institute
of Medicine has concluded that, at this
time, the data in humans are insufficient
to conclude that vitamin D has effects
other than on bones, highlighting the
need for further study in this area (Ross
et al., 2011).
The effects of vitamin D on cutaneous
immunity are controversial. Some studies
have shown that topical application
of vitamin D can protect against UV-
induced DNA damage and diminish
its immunosuppressive effects. In con-
trast, other studies, including the one by
Schwarz et al. (this issue, 2012) in this
issue of the Journal of Investigative
Dermatology, have demonstrated that
vitamin D facilitates the development
of regulatory T cells (Tregs) and is neces-
sary for the production of T cells that
produce IL-17 (Th17 cells) and IL-9 (Th9)
(Palmer et al., 2011). In support of the
concept that vitamin D downregulates
immune responses are clinical studies
showing that the concentration of vita-
min D correlates with the level of Treg
in the peripheral blood of patients
with multiple sclerosis (Royal Iii et al.,
2009). Epidemiologic studies have sug-
gested that individuals with vitamin D
deficiency are predisposed to a variety
of other autoimmune diseases, including
inflammatory bowel disease, systemic
lupus erythematosus, multiple sclerosis,
and type I diabetes (Arnson et al., 2007).
The conflicting observations may result
from differences in experimental systems
and treatment regimens, the complex
mechanisms by which vitamin D can
act on innate and adaptive immunity
(Hart et al., 2011), or polymorphisms in
nuclear or membrane receptors for
vitamin D among individuals.
Similar to vitamin D, UVB radiation
has been shown to modulate immune
function, an observation that was made
nearly 40 years ago and that gave rise
to the discipline of photoimmuno-
logy (Krutmann and Elmets, 1995). The
effects of UVB on the immune system
help to explain the greatly increased
incidence of non-melanoma skin cancer
in organ transplant recipients, the efficacy
of phototherapy in immunodermato-
logical disorders, and the pathogenesis
of a number of photosensitivity disorders
such as polymorphous light eruption.
After UV radiation exposure, immuno-
suppressive cytokines are produced
and alterations in cutaneous antigen-
presenting cells occur, shifting the
balance in the T-cell-mediated immune
response to one in which regulatory,
rather than effector, T cells predo-
minate. The Tregs that develop after
the introduction of antigens to UVB-
irradiated skin have been well charac-
terized (Elmets et al., 1983; Schwarz,
2008). They are Fox-p3þ , and they
express the CD4 and CD25 phenotypic
markers; they are antigen specific and,
once activated, produce the cytokine IL-
10, which is, at least in part, responsible
for their immunosuppressive activities.
The generation of Tregs by UVB
radiation requires dendritic cells (DCs)
in the skin. These cells, in most circum-
stances, are responsible for presentation
of antigens to both effector and Tregs.
However, after UVB radiation expo-
sure, their antigen-presenting function
becomes biased toward the generation
of Tregs (Schwarz et al., 2010). The
evolutionary rationale for this response
to UVB exposure is uncertain, but it
may result from efforts to protect against
autoimmune diseases such as polymor-
phous light eruption and lupus erythema-
tosus. There are multiple DC populations
in the skin. Two of these populations—
epidermal Langerhans cells and dermal
langerinþ DCs—have distinct functions
in the induction and regulation of cuta-
neous immune responses. Specifically,
epidermal Langerhans cells are required
for the development of UVB-induced
Tregs; on the other hand, evidence sug-
gests that dermal langerinþ DCs are
important for effector T-cell responses.
Speculation on the molecular target
for the photoimmunological effects of
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UVB radiation has centered on DNA
damage and its repair, although other
molecules, such as platelet-activating
factor, cis-urocanic acid, and noncoding
regions of RNA, have also been impli-
cated (Sreevidya et al., 2010; Bernard
et al., 2012). Given the similarity in the
effects of vitamin D and UVB radiation
on the cutaneous immune system, and
the fact that wavelengths within the
UVB are responsible for synthesis of
vitamin D from 7-deoxycholesterol, it
is not surprising for vitamin D to be
proposed as an additional mediator of
the immunosuppressive effects of UVB
radiation. Schwarz et al. (2012) have
carefully addressed this issue. They
evaluated the immunological effects of
vitamin D in a well-established system
of cutaneous T-cell-mediated immunity.
They observed that topical applica-
tion of 1a, 25-dihydroxyvitamin D3
can induce immunosuppression with
features that mirror those of UVB radi-
ation, but that the mechanism by which
immunosuppression is induced appears
to be distinct. The findings are consis-
tent with studies in animal models
showing that UV radiation suppresses
experimental autoimmune encephalo-
myelitis independent of vitamin D
production (Becklund et al., 2010).
Schwarz et al. (2012) were able to
show that topically applied 1a, 25-
dihydroxyvitamin D3 had an inhibitory
effect on the induction of contact
hypersensitivity. This effect was medi-
ated by antigen-specific Foxp3þ Tregs.
It has been shown that vitamin D alters
the function of DCs in the activation
of T cells and the induction of cell-
mediated immune responses (Hart et al.,
2011). Schwarz et al. (2012) confirmed
that finding; moreover, they showed that
Langerhans cells have a major role in
both suppression of contact hypersensi-
tivity and in the development of
Foxp3þ Tregs. However, UVB-induced
immune suppression was not abolished
in vitamin D receptor–deficient mice.
The inference of this finding is that
UV irradiation and vitamin D induce
immunosuppression differently.
Further studies will be required to
establish whether vitamin D has effects
in vivo in humans similar to those
observed in mice. Vitamin D has been
found to regulate the differentiation and
function of both epidermal Langerhans
cells and dermal DCs in humans
(Schauber and Gallo, 2008; Hart et al.,
2011) and, when compared with UVB,
to induce the development of different
types of Tregs (van der Aar et al., 2011).
What are the clinical implications of
the study? Topical vitamin D analogs
are already used to treat psoriasis, a
disease in which an overactive immune
response is known to have a pathogenic
role. The findings of Schwarz et al.
(2012) suggest that one mechanism
by which topical vitamin D analogs
work in psoriasis is through effects on
immunity, by augmenting the induc-
tion of Tregs, and/or through effects on
epidermal Langerhans cells. Consistent
with the finding that vitamin D and UVB
(which is also used to treat psoriasis)
lead to the generation of Tregs through
different mechanisms are clinical studies
demonstrating that the combination
of UVB and topical vitamin D analog
treatment can improve therapeutic
efficacy in psoriasis beyond that of
either alone.
There are anecdotal reports and small
series of the use of vitamin D for other
immunologically mediated cutaneous
diseases, such as morphea and vitiligo.
The findings of the current study provide
a rationale for expanded clinical trials
examining the use of topical vitamin D
in these and other diseases for which
current therapy is suboptimal.
UVB radiation has many different
effects on the skin (such as damage to
DNA), which increases its toxicity when
used as a therapeutic agent. Topically
applied vitamin D analogs do not cause
DNA damage; in fact, they may increase
DNA damage repair mechanisms.
Although it appears that UVB and vita-
min D cause immunosuppression by
distinct mechanisms, the end results in
terms of Treg and Langerhans cell effects
are similar. Therefore, it may be possible
to substitute topical vitamin D for UVB
phototherapy in some diseases, thereby
minimizing the DNA-damaging effects
of therapy.
Finally, Schwarz et al.’s (2012) obser-
vation that vitamin D is instrumental
in the development of Tregs, which
requires signaling through the vitamin
D receptor, and the fact that there are
vitamin D receptor polymorphisms that
affect the biological response to vitamin
D could explain, at least in part, the
genetic susceptibility to such immuno-
logically mediated skin diseases, such as
psoriasis, melanoma, or non-melanoma
skin cancer.
Collectively, Schwarz et al. (2012)
demonstrate that topical vitamin D can
induce antigen-specific Treg cells through
a mechanism dependent on Langerhans
cells. Although both UVB irradiation and
topical vitamin D induce immunosup-
pression, the ways in which they do so
are distinct. The study not only provides
new information for the understanding of
vitamin D–mediated immunosuppression
but also provides a rationale for the
potential application of vitamin D or its
combination with UVB phototherapy in
treating immunodermatological diseases.
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Tyrosinase: A Central Regulatory
Protein for Cutaneous Pigmentation
Yoon-Soo Cindy Bae-Harboe1 and Hee-Young Park1
Cutaneous pigmentation or skin color is the body’s natural protection against sun-
induced damage. Skin color is determined primarily by melanin, a biopolymer that
is synthesized within epidermal melanocytes, packaged in cellular organelles
called melanosomes, and then dispersed to neighboring keratinocytes. The
process of melanogenesis involves numerous molecules and intracellular path-
ways that are subject to regulation by endogenous and exogenous factors.
Tyrosinase is the central and rate-limiting enzyme in melanin biosynthesis.
Therefore, elucidation of the molecules and pathways that regulate tyrosinase
levels and activity could identify target areas for the development of compounds
to decrease excessive pigmentation on one hand or induce pigmentation on the
other. The following commentary will summarize the key regulatory molecules
and pathways involved in tyrosinase function.
Journal of Investigative Dermatology (2012) 132, 2678–2680. doi:10.1038/jid.2012.324
Tyrosinase
The human tyrosinase gene is about 50kb
long and is composed of 5 exons and 4
introns, whereas tyrosinase messenger
RNA (mRNA) is B2kb long (genebank
access number NM_000372). The nascent
chain of the newly synthesized tyrosinase
protein is glycosylated, folded in the
endoplasmic reticulum (ER), and directed
to melanosomes, the organelles residing
within melanocytes where melanin synth-
esis takes place (Park and Yaar, 2012).
Tyrosinase spans the melanosomal
outer membrane and has three domains:
an inner melanosomal domain that con-
tains the catalytic region of the enzyme,
a short melanosomal transmembrane
domain, and a cytoplasmic domain.
The cytoplasmic domain is composed
of aB30 amino acids, and it is required
to properly traffick tyrosinase into mela-
nosomes (Beermann et al., 1995).
Two types of melanin are synthesized
within melanosomes: eumelanin and
pheomelanin. Eumelanin is dark, brown-
black, and insoluble, whereas pheomela-
nin is light, red-yellow sulfur-containing,
and soluble. Tyrosinase is the rate-limiting
enzyme in melanin biosynthesis. It cata-
lyzes the conversion of tyrosine through
oxidation to L-dihydroxyphenylalanine and
requires copper for its activation. Inhibition
of this oxidation reaction blocks melanin
synthesis (Park and Yaar, 2012). Hydro-
quinone, the most frequently used drug to
treat hyperpigmentation in the United
States, is a pseudosubstrate for tyrosinase,
thus inhibiting tyrosinase activity.
The final steps in cutaneous pigmen-
tation are the transfer of melanin-con-
taining melanosomes from melanocytes
to neighboring keratinocytes, and their
dispersion within keratinocytes. Proper
dispersal of melanosomes is required for
normal skin color and for protective
pigmentation. Melanosomes are phago-
cytosed by keratinocytes, which is faci-
litated by a seven-transmembrane G
protein–coupled receptor called protease
activated receptor-2 (PAR-2). PAR-2 is
present on the keratinocyte membrane
and is activated by serine proteases that
cleave the extracellular portion of the
receptor, exposing a new segment that
acts as a tethered (attached) ligand,
increasing keratinocyte phagocytic acti-
vity (Nystedt et al., 1994).
Regulating tyrosinase expression and/or
activity
A key transcription factor for tyrosinase
is the microphthalmia-associated trans-
cription factor (MITF) that, when upre-
gulated, increases tyrosinase expression.
MITF has also been intimately linked
with melanocyte survival (Park and
Yaar, 2012); thus, the effects of MITF
extend beyond melanogenesis per se.
Alpha-melanocyte-stimulating hormone
(a-MSH), one of the first recognized
positive regulators of mammalian pig-
mentation, upregulates the expression
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